Citrus Oncology has been selected to be a part of the prestigious 2025 CancerX Accelerator Cohort

Cary, NC — Citrus Oncology, a tech-enabled, physician-led specialty care network focused on managing cancer-related comorbidities and treatment toxicities, has been selected as one of just 14 startups nationwide to join the highly competitive 2025 CancerX Accelerator cohort.

The CancerX Accelerator, part of the Cancer Moonshot initiative launched by the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH), is co-hosted by Moffitt Cancer Center and Digital Medicine Society (DiMe). The program supports digital health and AI innovators committed to transforming the future of cancer care.

This year’s cohort was selected from over 100 applicants and vetted by 45 expert judges representing 14 leading healthcare organizations. Finalists underwent 47 live pitch sessions before Citrus Oncology was selected for its groundbreaking model integrating timely, multidisciplinary specialty support for cancer patients.

“We’re honored to join the CancerX Accelerator and work alongside national leaders in oncology and digital health,” said Dr. Afreen Shariff, Co-Founder of Citrus Oncology. “Cancer patients are often dealing with more than just their tumors—co morbidities like diabetes, thyroid disease, heart complications, and immune-related toxicities are common and under-addressed. Citrus exists to close that gap.”

Through the program, Citrus Oncology will receive tailored mentorship, partnership opportunities, and strategic guidance from CancerX Champions—including 7 major health systems and 2 federal health agencies.

Citrus Oncology delivers rapid access to U.S. board-certified subspecialists across onco-endocrinology, cardio-oncology, rheumatology, dermatology, and palliative care. Its virtual-first approach empowers oncology teams to reduce hospitalizations, prevent treatment delays, and improve quality of life for patients navigating complex side effects.

The four-month accelerator program will culminate in a national showcase at the CancerX Demo Day in Fall 2025, where participating companies will present their validated models to stakeholders across the oncology innovation ecosystem.

For more information about Citrus Oncology, visit www.citrusoncology.com.

Link to CancerX 2025 press release: https://cancerx.health/our-work/2025-accelerator-cohort